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Over the past decade, the advancements in massively parallel sequencing have pro-
vided a new paradigm in biomedical research to uncover the genetic basis of human 
diseases. Integration of ‘omics information has begun transforming clinical management 
of cancer patients in terms of diagnostics and treatment options, giving rise to the era of 
precision medicine. Currently, nucleic acids for molecular profiling for patients diagnosed 
with hepatocellular carcinoma (HCC) are typically obtained from resected tumor mate-
rials or transplanted neoplastic liver and occasionally from biopsies. Given the intrinsic 
risks associated with such invasive procedures, circulating cell-free DNA (cfDNA) has 
been proposed as an alternative source for tumor DNA. Circulating cfDNA is a type of 
cell-free nucleic acid that derives from apoptotic, necrotic, as well as living eukaryotic 
cells. Importantly, the detection of abnormal forms of circulating cfDNA that originate 
from cancer cells provides a new tool for cancer detection, disease monitoring, and 
molecular profiling. Currently, cfDNA is beginning to be adopted into clinical practice 
as a non-invasive tool to monitor disease by tracking the evolution of disease-specific 
genetic alterations in several major cancer types. Moreover, cfDNA is demonstrating 
potential clinical value as a surrogate to assess the molecular makeup of tumors and 
to overcome the sampling biases inherent to intra-tumor genetic heterogeneity, espe-
cially in the metastatic setting. With the improvements in ‘omics and molecular biology 
techniques, coupled with the increasing understanding in the molecular pathogenesis of 
cancer, it can be anticipated that the detection and analysis of cfDNA will become more 
specific and sensitive and thus enable cfDNA analysis to be used as a diagnostic aid in 
patients with early-stage disease and perhaps even in a screening setting. In this review, 
we provide an overview of the latest findings on the role and potential utility of cfDNA 
analysis in the diagnosis, management, and screening of HCC.
Keywords: cell-free DNA, circulating tumor DNA, hepatocellular carcinoma, liquid biopsy, somatic mutations, 
copy number alterations, methylation
Review CRiTeRiA
Review of the literature was performed in English using the PubMed database. Search terms used 
included “hepatocellular carcinoma,” “liver cancer,” “circulating cell free DNA,” “circulating tumor 
DNA,” “plasma,” “serum,” and “liquid biopsy.”
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iNTRODUCTiON
Over the past decade, the advancements in next-generation 
sequencing (NGS) and high-throughput omics profiling have 
provided a new paradigm in biomedical research to uncover 
the epi/genetic basis of human diseases. Integration of omics 
information has begun to transform clinical management of 
cancer patients in terms of diagnostics, prevention, and treatment 
options, giving rise to the era of precision medicine. Compared to 
cancer types such as those of the breasts and the lungs, precision 
medicine for hepatocellular carcinoma (HCC) patients is lagging 
behind, owing to a number of HCC-specific challenges in clinical 
practice and the lack of treatment options.
Hepatocellular carcinoma accounts for >90% of liver can-
cers and was responsible for an estimated 782,000 new cancer 
cases and nearly 746,000 deaths in 2012 (1). While HCC is the 
sixth most common cause of cancer worldwide, it is the third 
most common cause of cancer deaths and has one of the high-
est mortality-to-incidence ratios (2). HCC usually occurs in 
cirrhotic livers, and the epidemiology of HCC shows marked 
variations between geographical regions and racial groups (3). 
In sub-Saharan Africa and south-east Asia, hepatitis B virus 
(HBV) chronic infection is endemic and accounts for the major-
ity of HCCs diagnosed (2). In Western populations, the rising 
incidence of HCC is in part driven by the increasing prevalence 
of chronic liver diseases associated with hepatitis C virus (HCV) 
infection, alcohol consumption, diabetes, obesity, and non-
alcoholic fatty liver disease (2, 4, 5). Other known risk factors of 
HCC include hereditary diseases such as hemochromatosis and 
α-1-antitrypsin deficiency, exposure to aflatoxin B1 through 
dietary consumption, smoking, and the male gender (2). The 
5-year cumulative risk for HCC in patients with cirrhosis ranges 
between 5 and 30%, depending on the cause (with the highest 
risk among those infected with HCV), region or ethnic group 
(17% in the United States and 30% in Japan), and stage of cirrho-
sis (with the highest risk among patients with decompensated 
disease) (6).
The stagnating prognosis of HCC is contributed in part by 
the limited treatment options. For early-stage HCC, curative 
treatment options involve resection and/or liver transplantation, 
with >50% 5-year overall survival. By contrast, for patients with 
late-stage unresectable disease or ineligible for transplantation, 
5-year overall survival is <10%. Treatment options may include 
transarterial chemoembolization (TACE) and radiofrequency 
ablation. In terms of systemic treatment, the multi-kinase inhibitor 
sorafenib is the only first-line agent for HCC, but it only extends 
survival by 2.8 months in late-stage patients (7). Regorafenib (a 
multi-kinase inhibitor) (8) and nivolumab (a PD-1 inhibitor) (9) 
were recently approved as second-line treatment in patients who 
progressed on sorafenib, bringing the total number of approved 
systemic agents to three, still far fewer than most other cancer 
types.
Hepatocarcinogenesis is a complex, multi-step process of 
histologic transformation of normal hepatocytes to HCC, involv-
ing the accumulation of epi/genetic alterations in hepatocytes 
(10). In this review, we summarized some of the challenges in the 
diagnosis and clinical management of HCC, assessed the current 
status of circulating cell-free DNA (cfDNA) as a “liquid biopsy” in 
HCC, and discussed the outlook of how circulating cfDNA may 
address some of the challenges in the clinic.
CLiNiCAL CHALLeNGeS iN LiveR 
CANCeR
In the context of precision medicine, one of the biggest chal-
lenges in HCC clinical management is the frequent lack of tumor 
tissue for molecular profiling. Tumor materials may be obtained 
during resection and/or transplantation. However, these 
procedures are restricted to patients with early-stage, limited 
HCC (11). Unlike most other solid tumor types, the diagnosis 
of HCC does not always require the histopathologic analysis of 
tumor tissue. This is particularly true for patients with a known 
background of cirrhosis. In cirrhotic patients, HCC is frequently 
diagnosed on radiology alone or with serum alpha-fetoprotein 
(AFP) levels (11). Consequently, tumor materials for genetic 
profiling are unavailable for many unresectable HCC patients. 
Indeed, molecular profiling studies of HCC tumor tissues are 
frequently biased toward resectable tumors (12–23). Moreover, 
biopsy and surgical intervention are invasive procedures, and 
thus longitudinal sampling for the purpose of disease monitor-
ing is clinically not feasible nor warranted in nearly all cases. 
An alternative source of DNA for molecular profiling would be 
highly desirable.
Early detection from screening programs has been reported 
to confer a survival benefit in HCC patients (24, 25). Currently, 
the most widely used blood-based biomarker is serum AFP. 
The clinical utility of AFP for diagnosis, even in the screening 
setting of high-risk patients, is limited by its lack of sensitiv-
ity and specificity. In fact, a substantial proportion of HCC 
patients do not display elevated serum AFP levels, while 
patients with chronic liver disease may also show elevated 
levels (26). Indeed, AFP is not currently recommended as the 
sole diagnostic marker (11).
Like virtually all solid tumors, variable levels of intra-tumor 
genetic heterogeneity with branched and parallel evolutionary 
patterns have been detected in HCC patients (27, 28). Genetic 
diversity appears to show spatial organization, with intrahepatic 
metastases showing rapid diversification at the distant site (28). 
HCC may also metastasize to distant organs, most frequently to 
the lungs, the lymph nodes, bone, and the adrenal glands. To add 
to the complexity, recurrent or multifocal HCC may represent 
intrahepatic metastasis, in which the malignant cells are dissemi-
nated from a single primary tumor or may represent independent 
(multi-centric) tumors (29). Clinical distinction between these 
two entities is important as intrahepatic metastases are likely to 
be more poorly differentiated and aggressive. Molecular analysis 
based on whole-genome sequencing in a recent study of 20 
patients with synchronous or metachronous disease within the 
liver found that 65% (13/20) patients had evidence of multi-
centric tumors (29). The direct clinical implication of intra-tumor 
genetic heterogeneity and multi-centricity is that a single biopsy 
may be inadequate to give a representative portrait of the epi/
genomic landscape of the disease.
FiGURe 1 | Circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs). Figure illustrates the origin of circulating cfDNA and CTCs. Circulating cfDNA may 
be released by apoptotic and necrotic cells, as well as through the secretion of living cells. In cancer patients, the fraction of tumor-derived cfDNA comprises 
circulating tumor DNA (ctDNA).
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wHAT iS CiRCULATiNG cfDNA?
Under the general nomenclature of “liquid biopsy,” the two main 
types are circulating tumor cells (CTCs) and cfDNA (Figure 1). 
CTCs refer to the intact tumor cells released into circulation. 
Analysis of CTCs offers the opportunity to study their behavior 
in experimental systems and to study them on the DNA, RNA, 
and protein levels (30). However, current methods detect only a 
few CTCs in a single blood draw of 7.5 ml (31, 32), limiting their 
clinical utility.
By contrast, circulating tumor DNA (ctDNA), the fraction 
of cfDNA derived from tumor cells, appears to be more readily 
detectable than CTCs (33). Most circulating cfDNA fragments 
are 160–180 base pair fragments, roughly the size of a mono-
nucleosomal unit, suggesting that they are largely released by 
apoptotic cells (34, 35). In most cases, white blood cells are the 
biggest contributor of cfDNA in the plasma (36). By contrast, 
ctDNA should in theory harbor the same epi/genetic alterations 
as the originating tumor cells. Interestingly, HCC patients have 
been reported to have aberrantly shorter and longer cfDNA frag-
ments, with the shorter fragments likely to have derived from 
tumor cells, while the longer fragments are hypothesized to have 
derived from necrotic cells (35).
Studies of the potential clinical utility of cfDNA are based on 
the hypothesis that abnormal forms of circulating cfDNA are 
more likely to be present in cancer patients. Both plasma-derived 
and serum-derived cfDNA/ctDNA have been and are being 
investigated as potential blood-based biomarkers for diagnosis, 
prognosis, and as a surrogate for molecular profiling in HCC 
(Table 1).
QUANTiTATive ANALYSiS OF cfDNA iN 
HePATOCeLLULAR CARCiNOMA
The initial description of elevated cfDNA concentration in 
cancer patients (59, 60) led the scientific community to further 
investigate the clinical utility of cfDNA concentration. In HCC, 
one of the first studies evaluating serum cfDNA concentrations 
in 52 HCV-associated HCC patients found that HCC patients 
had increased cfDNA concentrations compared to HCV carriers 
without known HCC and HCV-negative non-HCC individuals 
(40) (Table 1). The authors confirmed their findings in a follow-
up study with a larger cohort of 96 HCV-associated HCC patients 
and 100 HCV carriers without known HCC (44). Since then, stud-
ies have reported the concentration of cfDNA in serum or plasma 
to be 3–4 times higher in HCC patients compared to patients 
with chronic hepatitis (44, 49, 61) and nearly 20 times that of 
healthy controls (49). Several studies, including our own, have 
also reported that high cfDNA concentration was associated with 
larger tumors (40, 41, 58), higher tumor grade (40, 58), shorter 
overall survival (41, 44), and may serve as predictive biomarker 
for distant metastasis after curative surgery (44).
Attempts to use cfDNA quantification as a diagnostic tool have 
been more mixed, with one study reporting that cfDNA detection 
using quantitative PCR could discriminate HCC from normal 
controls with 90% sensitivity and 90% specificity (49). However, 
a meta-analysis found that cfDNA alone lacked robustness as 
the sole diagnostic tool for HCC, but its performance could be 
enhanced when used in conjunction with serum AFP levels (62). 
Importantly, quantitative analysis of cfDNA, as opposed to ctDNA, 
does not provide information into the biological characteristics 
and potential molecular targets of the HCC. Distinguishing 
ctDNA from cfDNA would require alternative approaches such as 
genomic and/or epigenomic analyses focusing on tumor-specific 
alterations.
MeTHYLATiON ANALYSiS OF ctDNA iN 
HePATOCeLLULAR CARCiNOMA
DNA methylation is a common heritable mark of epigenetic 
regulation in eukaryotic organisms involving the covalent trans-
fer of a methyl group to the C-5 position of the cytosine ring of 
TAbLe 1 | List of studies reporting on the analysis of circulating cfDNA in HCC patients.
Study Method cfDNA levels Methylation of 
ctDNA
Genetic alterations 
of ctDNA
Reference
Wong et al. Methylation-specific PCR of p16 √ (37)
Wong et al. Methylation-specific PCR of p15 and p16 √ (38)
Yeo et al. Methylation-specific PCR of RASSF1A √ (39)
Iizuka et al. Real-time PCR of GSTP1 √ (40)
Ren et al. cfDNA quantification and allelic imbalance of 8p √ (41)
Wang et al. Methylation-specific PCR of GSTP1 √ (42)
Tangkijvanich et al. Combined bisulfite restriction PCR for methylation of LINE-1  
repetitive sequences
√ (43)
Tokuhisa et al. Real-time PCR of GSTP1 √ (44)
Zhang et al. Methylation-specific PCR of RASSF1A, p15 and p16 √ (45)
Chan et al. Methylation-specific PCR of RASSF1A √ (46)
El-Shazly et al. Quantitative real-time PCR of Alu repeats √ (47)
Chen et al. Quantitative real-time PCR of beta-actin genomic DNA fragments √ (48)
Huang et al. Quantitative real-time PCR of cfDNA √ (49)
Chan et al. Whole-genome sequencing √ (50)
Chan et al. Genome-wide bisulfite sequencing √ √ (51)
Bettegowda et al. Safe-SeqS of tumor-specific somatic mutations √ (33)
Jiang et al. Whole-genome sequencing √ (35)
Ono et al. Real-time PCR of tumor-specific structural variations √ (52)
Ono et al. Whole-exome sequencing √ (52)
Sun et al. Genome-wide bisulfite sequencing √ √ (36)
Xu et al. Whole-genome sequencing √ (53)
Wen et al. MCTA-Seq √ (54)
Huang et al. ddPCR of four mutation hotspots √ (55)
Liao et al. Targeted sequencing of TERT, CTNNB1, and TP53 mutation hotspots √ (56)
Huang et al. Whole-exome multi-region sequencing and targeted deep sequencing √ (27)
Xu et al. Molecular inversion probes for aberrant methylation √ (57)
Ng et al. Targeted sequencing of 46 genes frequently altered in HCC √ (58)
PCR, polymerase chain reaction; ddPCR, digital droplet PCR; cfDNA, cell-free DNA; Safe-SeqS, safe-sequencing system; MCTA-Seq: methylated CpG tandems amplification and 
sequencing; ctDNA, circulating tumor DNA.
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DNA by DNA methyltransferases (63). Epigenetic mechanisms 
have been shown to play a pivotal role in the carcinogenesis of 
human tumors (64). It has been demonstrated that aberrant 
methylation of CpG islands serves as an important mechanism 
for the inactivation of tumor suppressor genes involved in hepa-
tocarcinogenesis (42, 65–67).
The first studies to use methylation status as a tumor-specific 
marker to detect ctDNA in HCC patients investigated the meth-
ylation status of the p15 and p16 genes (37, 38) (Table 1), both of 
which are frequently abrogated in human neoplasms (68, 69). In 
these studies, the authors found that p15 and p16 were methylated 
in 16% (4/25) and 59% (13/22), respectively, of the plasma/serum 
DNA (37, 38). Importantly, the authors demonstrated that all 
cases with evidence of p15/16 methylation in the plasma/serum 
DNA also showed evidence of methylation in the corresponding 
tumors (37, 38), suggesting that ctDNA reflects the epigenetic 
status of the originating tumors. On the other hand, not all HCC 
tumors with p15/p16 methylation were associated with the equiv-
alent methylation status in the plasma/serum DNA, underscoring 
the observation that ctDNA likely only accounts for a subset of 
cfDNA (36). Subsequent studies expanded the investigations to 
hypermethylation of the glutathione S-transferase P1 (GSTP1) 
and ras association domain family 1A (RASSF1A) genes (39, 42, 
45, 46) and hypomethylation of LINE-1 repetitive sequence (43). 
While hypermethylation of GSTP1 was detected in 50% (16/32) 
of the cfDNA (42), it appears that RASSF1A methylation was a 
more sensitive marker, with 70–93% of the sera of HCC patients 
showing evidence of hypermethylation (45, 46). It has also been 
reported that aberrant methylation in ctDNA may identify 
AFP-negative HCC (46). In agreement with the quantification of 
cfDNA, methylation studies have found that aberrant methyla-
tion is associated with increased risk of metastasis or recurrence 
(38), larger tumors (39, 43), and worse prognosis (43, 46).
More recent studies have taken advantage of NGS-based 
genome-wide survey of the methylation landscape to identify 
diagnostic and prognostic methylation markers suitable for 
ctDNA profiling. One such study described the use of meth-
ylated CpG tandems amplification and sequencing for the 
genome-wide detection of hypermethylated CpG islands in the 
cfDNA of HCC patients (54). The authors identified TGS10, 
ST8SIA6, RUNX2, and VIM as the best hypermethylated mark-
ers for the detection of small HCC (<3 cm) (54). Another study 
used The Cancer Genome Atlas methylation profiles of HCC 
tumors and an independent data set of normal blood leukocytes 
to construct a diagnostic prediction model using 10 methyla-
tion markers (57). When tested in the cfDNA, the diagnostic 
models created by these studies achieved 94% sensitivity and 
89% specificity in distinguishing HCC patients from cirrhotic or 
normal controls (54) and >83% sensitivity and >90% specific-
ity in distinguishing HCC patients from normal controls (57). 
Both studies detected aberrant methylation in a subset of or all 
AFP-negative HCC (54, 57). One of the studies also showed that 
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Frontiers in Medicine | www.frontiersin.org March 2018 | Volume 5 | Article 78
the diagnostic model could also differentiate HCC patients from 
those with liver diseases such as HBV/HCV infection and fatty 
liver disease and that the model scores correlated with tumor 
burden, treatment response, and disease stage (57).
On a more global scale, genome-wide hypomethylation is 
frequently observed in human cancer (51, 70). Genome-wide 
bisulfite sequencing of plasma-derived cfDNA showed that 
plasma methylation profiles among healthy individuals are fairly 
stable and did not show evidence of global hypomethylation 
(51). By contrast, plasma-derived cfDNA from predominantly 
HBV-positive and Barcelona Clinic Liver Cancer (BCLC) stage 
A HCC patients showed that a median of 34.1% (IQR 2.5–56.7%) 
of the genome was hypomethylated (51). These results illustrate 
that global hypomethylation associated with HCC is reflected in 
the cfDNA (51). Furthermore, cfDNA global hypomethylation 
as a marker to distinguish HCC patients from healthy indi-
viduals was reported to be 81% sensitive and 93% specific (51). 
Deconvolution of the methylation profiles suggests that while the 
liver contributes to ~10% of cfDNA in healthy individuals, the 
fraction rises to 24% (IQR 19.0–44.0%) in HCC patients (36). The 
variability among HCC patients is consistent with the substantial 
inter-individual variability in the proportion of hypomethylated 
genome (51), as it would be expected that the sensitivity to detect 
hypomethylation would be reduced in HCC patients with low 
fraction of ctDNA.
Besides being investigated as a diagnostic aid, methylation 
levels may also serve as a disease monitoring tool. For instance, 
rising serum concentrations of methylated RASSF1A have been 
reported in HBV carriers progressing to HCC (46). On the other 
hand, while it appears that methylation markers in the cfDNA are 
linked to the tumor, it is unclear whether they are derived directly 
from HCC tissue (54).
GeNeTiC ANALYSiS OF ctDNA iN 
HePATOCeLLULAR CARCiNOMA
Genomic characterization of HCC to the base pair resolution has 
revealed that no two HCCs harbor the same repertoire of somatic 
genetic alterations (13, 15, 16, 21–23). However, the somatic 
genetic alterations frequently found in HCC converge onto 
several main pathways, namely, p53 signaling (e.g., TP53 and 
CDKN2A), Wnt/β-catenin pathway (e.g., CTNNB1 and AXIN1), 
chromatin remodeling (e.g., ARID1A, ARID1B, ARID2, BAP1, 
MLL, MLL3, and PBRM1), response to oxidative stress (e.g., 
KEAP1 and NFE2L2), telomerase maintenance (e.g., TERT pro-
moter mutation, HBV integration into TERT, TERT fusion genes, 
and TERT copy number amplification), among others (21, 23). 
With therapeutic decisions being increasingly genotype-based, a 
number of studies have investigated the detection of ctDNA on 
the basis of somatic genetic alterations in HCC.
The proportion of HCC patients with detectable ctDNA based 
on somatic genetic alterations varies wildly between studies. Using 
direct sequencing, the TP53 R249S mutation could be detected in 
26% of the plasma DNA in an African HCC patient cohort (71). 
Using NGS investigating hotspot mutations in TERT promoter, 
CTNNB1, and TP53, tumor-associated mutations were detected 
in 8/41 (20%) plasma samples in a predominantly HBV-positive 
cohort (56) (Table 1). Interrogating TP53 c.747G>T (p.R249S), 
CTNNB1 c.121A>G (p.T41A) and c.133T>C (p.S45A), and 
TERT c.-124C>T promoter mutations using digital droplet 
PCR (ddPCR), ctDNA could be detected in 27/48 (56%) of the 
predominantly HBV-positive and BCLC stage A patients (55). 
Furthermore, copy number analysis found that 13/31 (42%) of 
HCC patients had detectable copy number alterations in the 
plasma (53). In the seminal study by Bettegowda et  al., it was 
reported that the fraction of advanced stage HCC patients with 
at least one detectable somatic mutation in the plasma was 75% 
(3/4), which was similar to other solid tumors of non-brain 
origin (33).
The variability in the proportion of HCC patients with detec-
table ctDNA appears to be related to cohort composition and 
geographical locations, as well as the methodologies for detec-
tion. Nonetheless, consistent with cfDNA quantification and 
methylation studies, detectable ctDNA on the basis of tumor-
specific genetic alterations is associated with well-established 
clinicopathologic parameters such as tumor size, AFP, and 
vascular invasion (52, 53, 56), as well as recurrence and extrahe-
patic metastasis (52, 56). Our own experience is largely consistent 
with these observations. In a recently published study of 30 HCC 
patients, we demonstrated that somatic mutations in genes fre-
quently genetically altered were detected in 27% (8/30) of patients 
and in 86% (6/7) of patients with large tumor (≥5 cm diameter) or 
metastatic disease (58). We also observed that detectable ctDNA 
on the basis of tumor-specific mutations was positively correlated 
with tumor size and Edmondson grade, although not with BCLC 
stage or AFP levels (58).
The fraction of ctDNA in cfDNA, estimated based on the 
fraction of sequences harboring tumor-associated mutations, 
also appears to vary substantially between patients. Among the 
patients with detectable ctDNA, ddPCR of four hotspot muta-
tions in TP53, CTNNB1, and TERT promoter found that the 
mutant allele fraction ranged from 0.33 to 23.7% (55). Our own 
NGS-based study identified mutant allele fractions from 0.06 to 
45% in the cfDNA among patients with detectable ctDNA (58). 
Based on copy number alterations and/or methylation, it was 
estimated that a median of 24.0% (range: 4.3–71.4%) of cfDNA 
was tumor-derived (36, 50). However, even between three HCC 
patients with advanced stage disease, there was enormous vari-
ability, with 7.2, 15, and 7,910 mutant fragments detected per 5 ml 
of plasma (33).
Analysis of tumor-specific genetic alterations has also 
allowed us to determine how well ctDNA would reflect the 
biology of the tumors. Indeed, whole-genome sequencing 
performed in the plasma-derived cfDNA suggests that the copy 
number profiles of plasma DNA highly resemble those of the 
matched primary tumor (35, 50). Furthermore, hotspot muta-
tions detected in the plasma DNA were almost always associated 
with the detection of the same mutations in the corresponding 
tumors (56). In our own study, comparing plasma-derived 
cfDNA and synchronously collected frozen biopsies from the 
primary tumor, we found that 87% (80/92) of the mutations 
were captured in the cfDNA among the seven patients in whom 
the largest tumor was ≥5 cm or was associated with metastasis 
(58). Importantly, we found that the proportion of mutations 
FiGURe 2 | Circulating tumor DNA (ctDNA) for early detection, disease monitoring, and molecular profiling. (A) ctDNA is being investigated as a marker for the 
detection of early hepatocellular carcinoma (HCC). A suitable marker for early detection in the screening setting would require excellent specificity. (b) The fluctuation 
of ctDNA level may be informative in assessing response to treatment and in detecting minimal residual disease. (C) ctDNA profiling may circumvent sampling 
biases resulting from intra-tumor genetic heterogeneity and multi-centric HCC.
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captured in the matched primary tumors of these patients was 
similar (95%, 87/92). Our results suggest that ctDNA reflects 
the biology of the primary tumors in patients with high disease 
burden. These findings are particularly important in the context 
of HCC, given that patients with high disease are the least likely 
to undergo surgical resection.
The more exciting recent development is the potential for 
ctDNA to circumvent the intra-tumor genetic heterogeneity 
in HCC (27, 28). Its potential was demonstrated with the use 
of whole-genome sequencing of the cfDNA from four HCC 
patients before surgery. The analysis revealed that 15–94% 
tumor-associated single nucleotide variants could be detected in 
the cfDNA, even at the very limited depth of 17× (50). Similarly, 
whole-exome sequencing of a patient with combined HCC/
cholangiocarcinoma found that 63% of the tumor-associated 
mutations were observed in the serum DNA (52). However, the 
tumor and the serum samples for this patient were collected 
2  years apart, which makes it difficult to assess whether the 
differences reflect the clonal evolution that may have occurred 
through two rounds of TACE (52). It may be argued that a 
synchronously collected cfDNA sample would have been more 
representative of the tumor. Indeed, synchronously collected 
cfDNA samples were representative of the primary tumors, but 
only in patients with high disease burden (58). We also found 
instances where mutations with low variant allele fraction 
(therefore almost certainly subclonal) in the primary tumors 
were readily detectable only in the cfDNA (58), suggesting that 
there is potential for ctDNA to circumvent the intra-tumor 
genetic heterogeneity.
The most comprehensive study to date to address the ques-
tion whether cfDNA captures intra-tumor heterogeneity was 
conducted by multi-region whole-exome sequencing of five 
patients (27). The authors found that the cfDNA captured 
most of the mutations that were heterogeneous between tumor 
regions, but only given the knowledge of the mutations present 
in the tumor (27). On the other hand, agnostic to the mutations 
in the tumor, the authors concluded that cfDNA was insufficient 
in capturing the heterogeneity of the disease but could be used 
to identify actionable mutations that were ubiquitous in the 
tumor (27).
Given the apparent correlation between ctDNA fraction 
and disease burden (33, 58), genomic profiling is also being 
investigated as a disease monitoring tool and for the detection of 
recurrence prior to clinical recurrence. Similar to cfDNA levels 
and methylation analysis of ctDNA, quantification of ctDNA on 
the basis of somatic genetic alterations showed that the ctDNA 
level mirrors response to treatment and disease progression, in 
that the ctDNA level dropped or completely disappeared after 
resection and rose prior to recurrence or metastasis (50–52). 
By contrast, in patients that remained in long-term remission, 
ctDNA was not detectable in long-term follow-up cfDNA sam-
ples (51, 52).
OUTLOOK: ADDReSSiNG CLiNiCAL 
PRObLeMS iN HCC
The characterization of ctDNA in HCC patients has focused on 
three main aspects: its potential for risk prediction or early cancer 
detection in a screening setting, for response to treatment and 
recurrence monitoring, and as a surrogate for tumor molecular 
profiling (Figure  2). With serum AFP levels being the only 
widely used but insensitive blood-based biomarker for HCC, a 
more sensitive and specific biomarker is highly desirable. While 
cfDNA level correlates with the disease stage and is easy to meas-
ure, it alone also lacks sensitivity and specificity (62). Moreover, 
elevated cfDNA level is not unique to HCC, as cfDNA level is 
also elevated in individuals with diabetes, stroke, acute trauma, 
pregnancy, among others (72).
Despite the increased sensitivity in detection methods, estab-
lishing the utility of ctDNA for risk prediction or early cancer 
detection in a screening setting remains challenging. Overcoming 
the challenges posed by the low fraction of ctDNA within cfDNA 
in early-stage HCC would be crucial. Thus far, a study of 50 HCC 
patients with repeated serum DNA sampling suggested that 
aberrant methylation could be detected up to 9 years prior to the 
diagnosis of HCC (45). There are a number of other anecdotal 
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examples to suggest that the detection of epi/genetic alterations 
in ctDNA may predate clinical diagnosis. For instance, whole-
genome sequencing of two cases without known HCC revealed 
the presence of copy number alterations in the plasma cfDNA, 
and the patients were diagnosed with HCC 3–4  months later 
(35). Large case–control studies required to establish the utility 
of ctDNA in early cancer detection are inherently difficult to 
carry out, as they will have to be prospective, will involve repeated 
sampling at regular intervals, and with long-term follow-up of 
the patients.
Developing a ctDNA test for early cancer detection would 
involve the selection of an appropriate marker broadly applicable 
for a given cohort. Highly recurrent hotspot mutations such as 
TP53 R249S, CTNNB1 amino acids D32, S33, S37, T41, and S45, 
and TERT c.-124C>T promoter mutations (13, 15, 16, 21–23) 
may serve as potential markers for HCC detection. However, 
the discovery of frequent TERT promoter mutation in cirrhotic 
pre-neoplastic lesions (73) suggests that it may lack specificity in 
a screening setting. An intriguing possibility could be to detect 
ctDNA on the basis of shorter fragment sizes (35), although it 
is currently unclear whether shorter fragment size is a universal 
feature of ctDNA.
Compared to early detection, ctDNA for response and recur-
rence monitoring is closer to clinical application. In other cancer 
types, ctDNA is being used to detect minimal residual disease (74) 
and to track the emergence of drug resistant clones (75). HCC 
patients often undergo repeated rounds of therapeutic interven-
tions such as TACE and ablation, with recurrence occurring 
several years later. Clonal evolution of the disease means that the 
genetic information obtained from tumor tissue at diagnosis or 
resection may become outdated by the time of recurrence. ctDNA 
profiling makes longitudinal monitoring of clonal evolution pos-
sible and may assist in the detection of micrometastatic disease 
(30). However, it should be noted that the timing of sample col-
lection is an important consideration in the interpretation of the 
analysis, as it has been shown that serum ctDNA peaks 4 weeks 
after TACE (52).
Circulating tumor DNA profiling holds promise as a surrogate 
to overcome the challenges posed by intra-tumor genetic het-
erogeneity. It has been hypothesized that the detection of TERT 
promoter, CTNNB1, and TP53 mutations in the plasma cfDNA 
but not in the HCC tumor may be attributed to intra-tumor 
genetic heterogeneity (55, 56). However, similar to the challenges 
faced in early detection, the ability to capture all somatic genetic 
alterations is hampered by the sensitivity of current technologies. 
For instance, whole-exome sequencing of a single HCC patient 
suggests that 63% of the mutations were shared between the 
resected tumor and the serum cfDNA 2 years post-surgery, but 
only 27% of the mutations would have been detected had the 
samples been analyzed independently (52). Similar observations 
were made in a multi-region whole-exome sequencing study of 
five HCC patients (27), highlighting the technical challenges in 
using ctDNA as a surrogate for molecular profiling in the absence 
of tumor tissue. However, it should be noted that the patients 
included in the studies had resectable disease. Given the correla-
tion of ctDNA and tumor burden, it is conceivable that a larger 
fraction of alterations would be represented and detectable in 
the ctDNA in late-stage patients. Indeed, we found that cfDNA 
profiling nearly recapitulated the repertoire of mutations detected 
in the primary tumors of patients with high disease burden (58), 
suggesting that the use of cfDNA for genetic profiling when 
biopsy is unavailable may be feasible in this subset of patients.
Currently, there are no widely accepted predictive markers 
for response to sorafenib or regorafenib. Response to immu-
notherapy such as nivolumab has been associated with tumor 
mutational burden (76). In fact, microsatellite instability status 
has recently been approved as an indication for nivolumab 
treatment of metastatic colorectal cancer (76). A subset of HCC 
exhibits a hypermutator phenotype (12, 21). With nivolumab 
approved as a second-line treatment, assessing mutational 
burden in the ctDNA of patients with advanced HCC should 
be feasible and may provide a predictive marker for response. 
Among our cohort of 30 patients, one HCC biopsy displayed 
a hypermutator phenotype, and the phenotype was clearly 
observed in the cfDNA (58). In addition, molecular analyses 
of ctDNA may uncover ubiquitous (i.e., present in all cancer 
cells) targetable genetic alterations that may quality patients for 
experimental therapy or off-label use. In a cohort of 70 HCC 
patients, 39% (27/70) harbored potential targetable alterations, 
including TSC1/TSC2 mutations (mTOR inhibitors), EGFR 
mutations (gefitinib and erlotinib), CCND1 amplifications and 
CDKN2A deletions or mutations (palbociclib), ATM mutation 
(olaparib), and MET amplification (tivantinib) (27). Using a 
more restricted targeted sequencing consisting of 46 coding and 
non-coding genes frequently altered in HCCs, we also detected 
a TSC2 frameshift mutation in the cfDNA and primary tumor of 
a metastatic patient (58).
Thus far, cfDNA profiling of HCC has focused on blood-based 
analysis (plasma and serum). It is plausible that ctDNA may also 
be detected in other body fluids, such as urine. Indeed, a recent 
study reported the use of qPCR-based analysis of TP53 c.747G>T 
(p.R249S) and aberrant methylation of the GSTP1 and RASSF1A 
genes in the urine of 10 HCC patients to monitor recurrence 
during follow-up (77). Of the five patients who were confirmed 
by MRI for recurrence, all had detectable changes in the urine 
cfDNA. Similar to plasma-derived cfDNA, the authors reported 
up to 9 months of lead-time prior to radiological recurrence (77). 
Compared to blood, urine is even more readily available. Further 
investigations into the use of urine would certainly be of clinical 
interest.
Through the analysis of cfDNA quantity, methylation, and 
genomic studies of ctDNA, it is clear that ctDNA holds potential 
to address a number of outstanding questions in the clinical 
management of HCC. Studies carried out thus far have laid the 
foundation for future studies into the use of ctDNA in early detec-
tion, response assessment, and detection of minimal residual 
disease. Exploiting ctDNA profiling to overcome the challenges 
posed by intra-tumor genetic heterogeneity may also provide 
biological insights into hepatocarcinogenesis.
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